An observational, register-based study on ticagrelor 60 mg persistence and event rates in clinical practice in the US and Europe.
Myocardial Infarction (MI)
N/A - 130 Years
Endpoint Classification: -
Intervention Model: Single Group Assignment
Primary Purpose: -
Verified 01 Apr 2022 by AstraZeneca
No locations available
Patients initiating ticagrelor 60 mg after an MI, with no prescription of ticagrelor 60 mg prior to their qualifying MI. The qualifying MI is defined as the most recent MI occurring before the first ticagrelor 60 mg prescription.
Patients not prescribed ticagrelor 60 mg at a comparable time point after an MI as matched patients in the ticagrelor cohort. Patients may be prescribed another P2Y12 inhibitor or aspirin alone.